Elamipretide Expanded Access Protocol Listed as Available

On October 16, 2026, ClinicalTrials.gov recorded an update to an expanded access protocol involving elamipretide. The listing, titled "An Intermediate Size Expanded Access Protocol of Elamipretide," carries the identifier NCT04689360. Its current status is marked as AVAILABLE. No phase is listed for this record, consistent with its classification as an expanded access protocol rather than a standard interventional trial. The update does not include any results, efficacy data, or safety findings. It reflects only a change in the availability status of this specific access pathway for elamipretide. Readers should note that expanded access protocols are distinct from clinical trials designed to test safety or effectiveness. They typically provide a mechanism for access to an investigational or approved treatment outside of standard trial enrollment. No additional details about enrollment criteria, timelines, or outcomes were included in this update. For further context on elamipretide, including its regulatory status and other associated trial activity, readers can consult the compound overview.